Arnold L. Demain

17.2k total citations · 6 hit papers
237 papers, 11.7k citations indexed

About

Arnold L. Demain is a scholar working on Molecular Biology, Pharmacology and Biotechnology. According to data from OpenAlex, Arnold L. Demain has authored 237 papers receiving a total of 11.7k indexed citations (citations by other indexed papers that have themselves been cited), including 158 papers in Molecular Biology, 93 papers in Pharmacology and 43 papers in Biotechnology. Recurrent topics in Arnold L. Demain's work include Microbial Natural Products and Biosynthesis (86 papers), Microbial Metabolic Engineering and Bioproduction (41 papers) and Enzyme Catalysis and Immobilization (30 papers). Arnold L. Demain is often cited by papers focused on Microbial Natural Products and Biosynthesis (86 papers), Microbial Metabolic Engineering and Bioproduction (41 papers) and Enzyme Catalysis and Immobilization (30 papers). Arnold L. Demain collaborates with scholars based in United States, Canada and Mexico. Arnold L. Demain's co-authors include Preeti Vaishnav, Sergio Sánchez, Jiangbin Wu, José L. Adrio, Evan Martens, Saul Wolfe, Yair Aharonowitz, Charles L. Cooney, Aiqi Fang and Eric A. Johnson and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Arnold L. Demain

234 papers receiving 11.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Production of recombinant proteins by microbes and higher organisms

2009 689 citations Arnold L. Demain, Preeti Vaishnav Biotechnology Advances profile →
Microbial drug discovery: 80 years of progress

2009 683 citations Arnold L. Demain et al. The Journal of Antibiotics profile →
Cellulase, Clostridia, and Ethanol

2005 650 citations Arnold L. Demain, Jiangbin Wu et al. Microbiology and Molecular Biology Reviews profile →
Natural products for cancer chemotherapy

2010 530 citations Arnold L. Demain, Preeti Vaishnav profile →
Microbial Enzymes: Tools for Biotechnological Processes

2014 446 citations Arnold L. Demain et al. profile →
The antibiotic resistance crisis, with a focus on the United States

2017 339 citations Evan Martens, Arnold L. Demain The Journal of Antibiotics profile →

Peers

Countries citing papers authored by Arnold L. Demain

Since Specialization

Citations

This map shows the geographic impact of Arnold L. Demain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnold L. Demain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnold L. Demain more than expected).

Fields of papers citing papers by Arnold L. Demain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnold L. Demain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnold L. Demain. The network helps show where Arnold L. Demain may publish in the future.

Co-authorship network of co-authors of Arnold L. Demain

This figure shows the co-authorship network connecting the top 25 collaborators of Arnold L. Demain. A scholar is included among the top collaborators of Arnold L. Demain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnold L. Demain. Arnold L. Demain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	useful-anti-cancer-agents-of-natural-product-origin/# 2017 ·Evan Martens, Arnold L. Demain, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
2	The antibiotic resistance crisis, with a focus on the United States breakdown → 2017 ·The Journal of Antibiotics ·Evan Martens, Arnold L. Demain	339
3	Production of valuable compounds by molds and yeasts 2016 ·The Journal of Antibiotics ·Arnold L. Demain, Evan Martens	41
4	Development of a semi-defined medium supporting production of platensimycin and platencin by Streptomyces platensis 2012 ·The Journal of Antibiotics ·(unknown), (unknown), (unknown), Maria E. Falzone, (unknown), Vincent P. Gullo, Arnold L. Demain	3
5	Creating Modern Industrial Microbiology 2011 ·Genetic Engineering & Biotechnology News ·Arnold L. Demain	1
6	Antimicrobial spectrum of the antitumor agent, cisplatin 2010 ·The Journal of Antibiotics ·(unknown), Shruti Saxena, (unknown), (unknown), Neil Auricchio, (unknown), (unknown), Arnold L. Demain	40
7	Unexpected applications of secondary metabolites 2010 ·Biotechnology Advances ·Preeti Vaishnav, Arnold L. Demain	91
8	Recombinant organisms for production of industrial products 2010 ·PubMed ·(unknown), Arnold L. Demain	107
9	REVIEWS: The business of biotechnology 2007 ·Industrial Biotechnology ·Arnold L. Demain	59
10	Cellulase, Clostridia, and Ethanol breakdown → 2005 ·Microbiology and Molecular Biology Reviews ·Arnold L. Demain, (unknown), Jiangbin Wu	650
11	Nutritional Studies on the Growth of the Rapamycin-Producing Streptomyces hygroscopicus 2003 ·Journal of Microbiology and Biotechnology ·Wan Seop Kim, Sean A. Davis, Grace Wong, Arnold L. Demain	3
12	Prescription for an ailing pharmaceutical industry 2002 ·Nature Biotechnology ·Arnold L. Demain	39
13	EDWARD P. ABRAHAM, Cell-free Systems and the Fungal Biosynthesis of Beta-lactams 2000 ·The Journal of Antibiotics ·Arnold L. Demain	1
14	Biotransformation of Compactin to Pravastatin by Actinomadura sp. 2966. 1997 ·The Journal of Antibiotics ·Yulin Peng, Jacob Yashphe, Arnold L. Demain	14
15	δ-(L-α-Aminoadipyl)-L-Cysteinyl-D-Valine Synthetase, the Multienzyme Integrating the Four Primary Reactions in β-Lactam Biosynthesis, as a Model Peptide Synthetase 1993 ·Nature Biotechnology ·Yair Aharonowitz, (unknown), Jesús M. Cantoral, Gerald Cohen, Arnold L. Demain, Uwe Fink, J. R. Kinghorn, Horst Kleinkauf, Andrew MacCabe, (unknown), Eva Pfeifer, Torsten Schwecke, Henk van Liempt, Hans von Döhren, Saul Wolfe, Jinyou Zhang	49
16	Regulation of biosynthesis of bacilysin byBacillus subtilis 1990 ·Journal of Industrial Microbiology & Biotechnology ·Gülay Özcengiz, N. Gürdal Alaeddinoğlu, Arnold L. Demain	31
17	Phosphate regulation of ACV synthetase and cephalosporin biosynthesis in Streptomyces clavuligerus 1989 ·FEMS Microbiology Letters ·(unknown), Saul Wolfe, Arnold L. Demain	28
18	The Importance of Thermophilic Bacteria in Biotechnology 1985 ·Critical Reviews in Biotechnology ·Juergen Wiegel, Lars G. Ljungdahl, Arnold L. Demain	122
19	Role of Citrate in Xanthan Production by Xanthomonas campestris 1980 ·Journal of Fermentation Technology ·(unknown), Arnold L. Demain	22
20	Resting-cell Studies on Carbon-source Regulation of β-Lactam Antibiotic Biosynthesis 1978 ·Journal of Fermentation Technology ·Arnold L. Demain, (unknown)	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact